Patent: 8,394,924
✉ Email this page to a colleague
Summary for Patent: 8,394,924
Title: | Directed engagement of activating Fc receptors |
Abstract: | The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR. |
Inventor(s): | Wittrup; K. Dane (Chestnut Hill, MA), Howland; Shanshan Wu (Singapore, SG) |
Assignee: | Massachusetts Institute of Technology (Cambridge, MA) |
Application Number: | 12/605,273 |
Patent Claims: | see list of patent claims |
Details for Patent 8,394,924
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | 09/14/1992 | ⤷ Try a Trial | 2028-10-23 |
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2028-10-23 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2028-10-23 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2028-10-23 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2028-10-23 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2028-10-23 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |